[{"orgOrder":0,"company":"Kura Oncology","sponsor":"Leukemia & Lymphoma Society","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Ziftomenib","moa":"||MEN1","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Leukemia & Lymphoma Society","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Leukemia & Lymphoma Society"}]

Find Clinical Drug Pipeline Developments & Deals for Idarubicin Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The collaboration aims to evaluate Kura’s menin inhibitor, KO-539 (ziftomenib), in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 12, 2023

                          Lead Product(s) : Ziftomenib,Fludarabine Phosphate,Idarubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Leukemia & Lymphoma Society

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          University Hospital, Montpellier

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          University Hospital, Montpellier

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 01, 2018

                          Lead Product(s) : Idarubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : GUERBET

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Centre Hospitalier Universitaire de Besancon

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Centre Hospitalier Universitaire de Besancon

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Lead Product(s) : Idarubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : UMR1098, EFS BFC, Besançon | Centre Henri Becquerel | Maisonneuve-Rosemont Hospital | Centre Hospitalier Universitaire Dijon | INSERM CIC1431

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 26, 2018

                          Lead Product(s) : Idarubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : UMR1098, EFS BFC, Besançon | Centre Henri Becquerel | Maisonneuve-Rosemont Hospital | Centre Hospitalier Universitaire Dijon | INSERM CIC1431

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 18, 2016

                          Lead Product(s) : Idarubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank